Oxford Biomedica 

$6.56
101
+$0.00+0%Friday 14:59

Statistics

Day High
7.35
Day Low
7.35
52W High
12.61
52W Low
5.8
Volume
2,000
Avg. Volume
2,384
Mkt Cap
792.01M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Sep 22Expected
Q1 2024
Q1 2024
Q2 2024
Q1 2025
Q2 2025
Q4 2025
Q2 2026
-114.95
-78.45
-41.95
-5.45
Expected EPS
-28.177110090368203
Actual EPS
-30.188696479685866

Financials

-18.32%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
229MRevenue
-41.96MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow OXBDF. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

About

Oxford Biomedica plc is a biopharmaceutical firm focused on the discovery, advancement, and sophisticated bioprocessing of innovative cell and gene therapies. Operating globally, with a strong presence across Europe, the company organizes its activities into two segments: Platform and Product. Its proprietary LentiVector platform technology facilitates the integration of genes into non-dividing cells, such as neurological cells in the brain and retinal cells in the eye, and can incorporate diverse therapeutic genes. The company's developmental pipeline includes promising candidates like Axo-Lenti-PD, a gene-based treatment for Parkinson's disease. Other pre-clinical stage programs feature OXB-302, targeting haematological tumors, and OXB-401, OXB-40X, and OXB-40Y, all addressing liver indications. Oxford Biomedica maintains numerous strategic alliances with prominent pharmaceutical entities such as Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Immatics, Arcellx, and the Vaccines Manufacturing and Innovation Centre. Additionally, it engages in research collaborations, including a partnership with Circularis Biotechnologies to identify novel tissue-specific promoters for in vivo lentiviral gene therapy, Virica Biotech for scaling viral medicines, Isolere Bio for enhancing downstream manufacturing efficiencies of biologics, and BiologIC Technologies for utilizing a novel biocomputer system in viral vector development. Founded in 1995, Oxford Biomedica plc is headquartered in Oxford, United Kingdom.
Show More
CEO
Frank Mathias
Employees
1017
Country
United Kingdom
ISIN
GB00BDFBVT43
WKN
000A2JLRX

Listings

0 Comments

Share your thoughts

FAQs

What is Oxford Biomedica stock price today?▼
The current price of OXBDF is $6.56 USD — it has increased by +0% in the past 24 hours. Watch Oxford Biomedica stock price performance more closely on the chart.
What is Oxford Biomedica stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Oxford Biomedica stocks are traded under the ticker OXBDF.
Is Oxford Biomedica stock price growing?▼
OXBDF stock has fallen by -10.76% compared to the previous week, the month change is a -2.11% fall, over the last year Oxford Biomedica has showed a -24.61% decrease.
What is Oxford Biomedica market cap?▼
Today Oxford Biomedica has the market capitalization of 792.01M
When is the next Oxford Biomedica earnings date?▼
Oxford Biomedica is going to release the next earnings report on April 15, 2027.
What were Oxford Biomedica earnings last quarter?▼
OXBDF earnings for the last quarter are -0.4 USD per share, whereas the estimation was -0.38 USD resulting in a -7.14% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Oxford Biomedica revenue for the last year?▼
Oxford Biomedica revenue for the last year amounts to 229M USD.
What is Oxford Biomedica net income for the last year?▼
OXBDF net income for the last year is -41.96M USD.
How many employees does Oxford Biomedica have?▼
As of November 22, 2026, the company has 1,017 employees.
In which sector is Oxford Biomedica located?▼
Oxford Biomedica operates in the Health & Wellness sector.
When did Oxford Biomedica complete a stock split?▼
The last stock split for Oxford Biomedica was on May 31, 2018 with a ratio of 1:50.
Where is Oxford Biomedica headquartered?▼
Oxford Biomedica is headquartered in Oxford, United Kingdom.